Consequently, we decided to add venetoclax, which was recently approved by the FDA in combination with hypomethylating agents or low-dose cytarabine for elderly individuals (75 years or older) with newly diagnosed AML or those who have comorbidities precluding intensive induction chemotherapy, to investigate whether BCL-2 inhibition enhanced the antitumor activity of the Eht1864/midostaurin combination therapy in FLT3-mutant AML. The gene discussed is BCL2; the disease is acute myeloid leukemia.